BioSpace News Archive

CB Scientific. Inc. (OTC PINK:CBSC), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, is pleased to announce that it has entered into a collaborative partnership agreement (CPA) with Shenzhen Semacare Medical Technology Co., Ltd.

- TCT conference visibility bolsters strong momentum as SIERRA nears full enrollment following recent positive interim analysis - Strong results from 75% of patient enrollment highlighted in CME events, oral presentations and investigator interactions at TCT

Lexaria Bioscience Corp. a global innovator in drug delivery platforms, announces significant progress in its 2021 applied research and development (R&D) program with additional focus on hypertension.

Ensoma, a company expanding the curative power of genomic medicine by pioneering a next-generation in vivo approach, today launched with a $70 million Series A financing led by co-founder and seed investor 5AM Ventures,

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the U.S. and European full market launch of the FITBONE ® intramedullary lengthening system for limb lengthening and deformity correction of the femur and tibia bones.

Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium - Combination of eganelisib with nivolumab demonstrated improved ORR, DCR, and PFS versus 2L standard of care nivolumab monotherapy -

Predictive Oncology Inc. announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 4,222,288 shares of its common stock, at a purchase price of $1.75 per share, for gross proceeds of approximately $7.4 million in a registered direct offering priced at-the-market under Nasdaq rules.

Eurofins launches a new CE marked serological assay for the identification and quantification of antibodies to SARS-CoV-2.

Desai to play a key role in helping guide the clinical research program for the company’s novel lead candidate RP-0320 and additional programs stemming from its MMA drug development platform

Antios Therapeutics, Inc. (“Antios”) today announced the appointment of Patrick T. Higgins to the company’s board of directors. Mr. Higgins is a highly accomplished biopharmaceutical executive with more than two decades of experience leading companies in the development of therapies to treat infectious diseases